Galderma announced the availability of Mirvaso (brimonidine) Topical Gel 0.33% in a new pump delivery system, designed to dispense a consistent dose with each use.
Mirvaso Gel is indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older. The active ingredient in Mirvaso Gel is brimonidine, a selective alpha-2 adrengeric agonist. Topical application of Mirvaso Gel may reduce erythema through direct vasoconstriction. The effects are typically seen within 30 minutes of application, and for some may continue for up to 12 hours.
Mirvaso Gel is available in 30g and 45g tubes and now in a 30g pump presentation.
For more information visit GalerdermaUSA.com.